Document Type : original article
Authors
- Setila Dalili 1
- Ghazaleh Sadat Aldaghi 2
- Shahin Koohmanaee 2
- Maryam Shahrokhi 3
- Mohammad Ali Esfandiari 4
- Seyed Amirreza Nemati 1
- Jafar Aldaghi 5
- Afagh Hassanzadeh Rad 2
- Houman Hashemian 2
1 Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
2 Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran
3 Department of clinical pharmacy, Faculty of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran
4 1. Student Research Committee, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran 2. Student research committee, Virtual School of Medical Education and Management, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
5 Department of Nutrition, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Abstract
Background: limited studies have been conducted on the effect of synbiotics supplementation on Type 1 Diabetes Mellitus (T1DM). The current study aimed to evaluate the impacts of synbiotic supplementation on glycemic parameters, lipid profile, and vitamin D levels in children with T1DM.
Methods: In this double-blind, randomized controlled trial, 86 T1DM patients aged 4-18 were randomly divided into two equal groups. One group received insulin and a synbiotic supplement once daily for 12 weeks; another group received insulin and a placebo. FBS (fasting blood sugar), HbA1C (hemoglobin A1c), triglycerides, cholesterol, HDL (High-density lipoprotein), LDL (low-density lipoprotein), and vitamin D levels were measured at the beginning and end of the study in both groups.
Results: The trend of FBS, HbA1C, triglycerides, cholesterol, HDL, LDL, and vitamin D changes was not significant over time in both groups. Based on the analysis of covariance, the means of FBS and HbA1C were lower in the intervention group (p=0.048 and 0.025, respectively). However, no significant changes in triglycerides, cholesterol, HDL, LDL, and vitamin D levels were observed between the two groups (p= 0.291, 0.291, 0.952, 0.140, and 0.557, respectively).
Conclusion: It's suggested that insulin treatment in combination with synbiotic supplementation could improve FBS and HbA1C in T1DM children but had no effects on lipid profile and vitamin D levels.
Keywords
- Caferoğlu Z, İnanç N, Hatipoğlu N, Kurtoğlu S. Health-related quality of life and metabolic control in children and adolescents with type 1 diabetes mellitus. Journal of clinical research in pediatric endocrinology. 2016; 8(1):67.
2. Nielsen DS, Krych Ł, Buschard K, Hansen CH, Hansen AK. Beyond genetics. Influence of dietary factors and gut
microbiota on type 1 diabetes. FEBS letters. 2014; 588(22):4234-43.
- Paun A, Yau C, Danska JS. Immune recognition and response to the intestinal microbiome in type 1 diabetes. Journal of autoimmunity. 2016; 71:10-8.
- Mottl AK, Divers J, Dabelea D, Maahs DM, Dolan L, Pettitt D, Marcovina S, Imperatore G, Pihoker C, Mauer M, Mayer-Davis EJ; SEARCH for Diabetes in Youth Study. The dose–response effect of insulin sensitivity on albuminuria in children according to diabetes type. Pediatric Nephrology. 2016; 31(6):933-40.
- Paun A, Danska JS. Modulation of type 1 and type 2 diabetes risk by the intestinal microbiome. Pediatric Diabetes. 2016; 17(7):469-77.
- De Goffau MC, Luopajärvi K, Knip M, Ilonen J, Ruohtula T, Härkönen T, Orivuori L, Hakala S, Welling GW, Harmsen HJ, Vaarala O. Fecal microbiota composition differs between children with β-cell autoimmunity and those without. Diabetes. 2013; 62(4):1238-44.
- de Goffau MC, Fuentes S, van den Bogert B, Honkanen H, de Vos WM, Welling GW, Hyöty H, Harmsen HJM. Aberrant gut microbiota composition at the onset of type 1 diabetes in young children. Diabetologia. 2014; 57(8):1569-77.
- Han H, Li Y, Fang J, Liu G, Yin J, Li T, Yin Y. Gut microbiota and type 1 diabetes. International Journal of Molecular Sciences. 2018; 19(4):995.
- Gibson GR, Scott KP, Rastall RA, Tuohy KM, Hotchkiss A, Dubert-Ferrandon A, Gareau M, Murphy E F, Saulnier D, Loh G, Macfarlane S, Delzenne N, Ringel Y, Kozianowski G, Dickmann R, Lenoir-Wijnkook I, Walker C, Buddington R.. Dietary prebiotics: current status and new definition. Food Sci Technol Bull Funct Foods. 2010; 7(1):1-19.
- Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM, Bindels LB, Vos WMd, Gibson GR, Thissen JP, Delzenne NM. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut. 2013; 62(8):1112-21.
- Kellow NJ, Coughlan MT, Reid CM. Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomized controlled trials. British Journal of Nutrition. 2014; 111(7):1147-61.
- Geurts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Beneficial microbes. 2014; 5(1):3-17.
- Ho J, Reimer RA, Doulla M, Huang C. Effect of prebiotic intake on gut microbiota, intestinal permeability and glycemic control in children with type 1 diabetes: study protocol for a randomized controlled trial. Trials. 2016; 17(1):1-8.
- Wang G, Liu J, Xia Y, Ai L. Probiotics-based interventions for diabetes mellitus: A review. Food Bioscience. 2021; 43:101172.
- Rajkumar H, Kumar M, Das N, Kumar SN, Challa HR, Nagpal R. Effect of Probiotic Lactobacillus salivarius UBL S22 and Prebiotic Fructo-oligosaccharide on Serum Lipids, Inflammatory Markers, Insulin Sensitivity, and Gut Bacteria in Healthy Young Volunteers: A Randomized Controlled Single-Blind Pilot Study. J Cardiovasc Pharmacol Ther. 2015; 20(3):289-98.
- 16. Asemi Z, Khorrami-Rad A, Alizadeh SA, Shakeri H, Esmaillzadeh A. Effects of synbiotic food consumption on metabolic status of diabetic patients: a doublediabetic patients: a double-blind
randomized cross-over controlled clinical trial. Clin Nutr. 2014; 33(2):198-203.
- Mahboobi S, Rahimi F, Jafarnejad S. Effects of prebiotic and synbiotic supplementation on glycaemia and lipid profile in type 2 diabetes: a meta-analysis of randomized controlled trials. Advanced pharmaceutical bulletin. 2018; 8(4):565.
- Zare Javid A, Aminzadeh M, Haghighi-Zadeh MH, Jamalvandi M. The Effects of Synbiotic Supplementation on Glycemic Status, Lipid Profile, and Biomarkers of Oxidative Stress in Type 1 Diabetic Patients. A Placebo-Controlled, Double-Blind, Randomized Clinical Trial. Diabetes Metab Syndr Obes. 2020; 13:607-17.
- Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol. 2014; 16(7):1024-33.
- Harsch IA, Konturek PC. The Role of Gut Microbiota in Obesity and Type 2 and Type 1 Diabetes Mellitus: New Insights into "Old" Diseases. Med Sci (Basel). 2018; 6(2).
- Rampanelli E, Nieuwdorp M. Gut microbiome in type 1 diabetes: the immunological perspective. Expert Rev Clin Immunol. 2023; 19(1):93-109.
- Gavin PG, Hamilton-Williams EE. The gut microbiota in type 1 diabetes: friend or foe? Curr Opin Endocrinol Diabetes Obes. 2019; 26(4):207-12.
- Murri M, Leiva I, Gomez-Zumaquero JM, Tinahones FJ, Cardona F, Soriguer F, Queipo-Ortuño MI. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Med. 2013; 11:46.
- Del Chierico F, Rapini N, Deodati A, Matteoli MC, Cianfarani S, Putignani L. Pathophysiology of Type 1 Diabetes and Gut Microbiota Role. Int J Mol Sci. 2022; 23(23).
- Wang Z, Li W, Lyu Z, Yang L, Wang S, Wang P, Song F, Chen K, Huang Y. Effects of probiotic/prebiotic/synbiotic supplementation on blood glucose profiles: a systematic review and meta-analysis of randomized controlled trials. Public Health. 2022; 210:149-59.
- Mishra S, Wang S, Nagpal R, Miller B, Singh R, Taraphder S, Yadav H. Probiotics and prebiotics for the amelioration of type 1 diabetes: present and future perspectives. Microorganisms. 2019; 7(3):67.
- Kooshki AA, Tofighiyan T, Rakhshani MH. Effects of synbiotics on inflammatory markers in patients with type 2 diabetes mellitus. Global journal of health science. 2015; 7(7):1.
- Eslamparast T, Zamani F, Hekmatdoost A, Sharafkhah M, Eghtesad S, Malekzadeh R, Poustchi H. Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome: a randomised, double-blind, placebo-controlled pilot study. British journal of nutrition. 2014; 112(3):438-45.
- Asemi Z, Khorrami-Rad A, Alizadeh S-A, Shakeri H, Esmaillzadeh A. Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial. Clinical nutrition. 2014; 33(2):198-203.
- Tom Dieck H, Schön C, Wagner T, Pankoke HC, Fluegel M, Speckmann B. A synbiotic formulation comprising Bacillus subtilis DSM 32315 and L-alanyl-L-glutamine improves intestinal butyrate levels and lipid metabolism in healthy humans. Nutrients. 2021; 14(1):143.31. Nasli-Esfahani E, Nadjarzade A, Mozaffari-khosravi H. Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial.
Journal of Diabetes & Metabolic Disorders. 2017; 16(1):1-10.
- Moroti C, Souza Magri LF, de Rezende Costa M, Cavallini DC, Sivieri K. Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids in health and disease. 2012; 11(1):1-8.
- Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, Close KL. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes care. 2019; 42(3):400-5.
- Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes technology & therapeutics. 2019; 21(2):81-5.
)